Published in Proc Natl Acad Sci U S A on March 31, 2009
Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell (2013) 6.47
CpG methylation controls reactivation of HIV from latency. PLoS Pathog (2009) 2.51
Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology (2009) 2.20
Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton. Proc Natl Acad Sci U S A (2010) 2.07
Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage. Retrovirology (2010) 1.51
HIV-1 transcription and latency: an update. Retrovirology (2013) 1.49
Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells. Methods (2010) 1.29
HIV reservoirs and latency models. Virology (2011) 1.29
Cyclin T1 and CDK9 T-loop phosphorylation are downregulated during establishment of HIV-1 latency in primary resting memory CD4+ T cells. J Virol (2012) 1.08
Human immunodeficiency virus (HIV) latency: the major hurdle in HIV eradication. Mol Med (2012) 0.96
NF-κB/Rel: agonist and antagonist roles in HIV-1 latency. Curr Opin HIV AIDS (2011) 0.95
Quantitative phosphoproteomics reveals extensive cellular reprogramming during HIV-1 entry. Cell Host Microbe (2013) 0.93
Molecular Understanding of HIV-1 Latency. Adv Virol (2012) 0.90
Calcium/calcineurin synergizes with prostratin to promote NF-κB dependent activation of latent HIV. PLoS One (2013) 0.84
Transcriptional target-based expression cloning of immunoregulatory molecules. Immunol Res (2010) 0.78
Deployment of the human immunodeficiency virus type 1 protein arsenal: combating the host to enhance viral transcription and providing targets for therapeutic development. J Gen Virol (2012) 0.77
Heat Shock Protein 90 Facilitates Latent HIV Reactivation through Maintaining the Function of Positive Transcriptional Elongation Factor b (p-TEFb) under Proteasome Inhibition. J Biol Chem (2016) 0.76
An enhanced chimeric firefly luciferase-inspired enzyme for ATP detection and bioluminescence reporter and imaging applications. Anal Biochem (2015) 0.76
The two sides of Tat. Elife (2016) 0.75
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26
An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature (1987) 19.23
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science (1997) 15.12
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A (1997) 13.47
The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol (2004) 10.85
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75
Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci U S A (1989) 6.32
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75
Human immunodeficiency virus long terminal repeat responds to T-cell activation signals. Proc Natl Acad Sci U S A (1987) 3.47
The NF-kappa B binding sites in the human immunodeficiency virus type 1 long terminal repeat are not required for virus infectivity. J Virol (1989) 3.36
CARD11 mediates factor-specific activation of NF-kappaB by the T cell receptor complex. EMBO J (2002) 2.90
The biology of the Ets1 proto-oncogene. Mol Cancer (2003) 2.88
Molecular characterization, reactivation, and depletion of latent HIV. Immunity (2003) 2.80
Defective activation and survival of T cells lacking the Ets-1 transcription factor. Nature (1995) 2.46
Structural studies of Ets-1/Pax5 complex formation on DNA. Mol Cell (2001) 2.16
A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter. Nucleic Acids Res (2000) 2.16
Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS (1999) 2.09
Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. PLoS Pathog (2006) 2.08
Characterization of the cooperative function of inhibitory sequences in Ets-1. Mol Cell Biol (1996) 1.85
OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin Immunol (2001) 1.75
Physical interactions between Ets and NF-kappaB/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus enhancer in T cells. J Virol (1997) 1.71
Cooperative interaction of ets-1 with USF-1 required for HIV-1 enhancer activity in T cells. EMBO J (1998) 1.62
The kappaB sites in the human immunodeficiency virus type 1 long terminal repeat enhance virus replication yet are not absolutely required for viral growth. J Virol (1997) 1.59
Phosphorylation represses Ets-1 DNA binding by reinforcing autoinhibition. Genes Dev (2000) 1.48
NF-kappa B-dependent and -independent pathways of HIV activation in a chronically infected T cell line. Virology (1994) 1.47
Hide-and-seek: the challenge of viral persistence in HIV-1 infection. Annu Rev Med (2008) 1.45
The human ETS1 gene: genomic structure, promoter characterization and alternative splicing. Oncogene (1991) 1.44
Transcriptional profiles of latent human immunodeficiency virus in infected individuals: effects of Tat on the host and reservoir. J Virol (2003) 1.40
Raf-1 kinase targets GA-binding protein in transcriptional regulation of the human immunodeficiency virus type 1 promoter. J Virol (1996) 1.35
Attacking HIV provirus: therapeutic strategies to disrupt persistent infection. Infect Disord Drug Targets (2006) 0.86
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75
Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell (2013) 6.47
Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity (2012) 6.29
The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med (2002) 4.73
Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J Exp Med (2006) 4.62
Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol (2006) 4.27
Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA (2005) 4.24
Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog (2013) 4.05
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis (2007) 3.39
Phosphorylation of the CARMA1 linker controls NF-kappaB activation. Immunity (2005) 3.36
Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis (2004) 3.30
Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med (2008) 3.28
The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med (2007) 3.20
Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol (2004) 3.17
Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J Virol (2004) 3.13
Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol Biol (2005) 2.99
Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J Virol (2002) 2.89
Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J Virol (2003) 2.78
Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest (2009) 2.75
Experimental approaches to the study of HIV-1 latency. Nat Rev Microbiol (2007) 2.71
The multifactorial nature of HIV-1 latency. Trends Mol Med (2004) 2.68
G-->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol (2005) 2.61
Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity (2012) 2.56
Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells. J Virol (2005) 2.55
Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem (2011) 2.42
Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol (2002) 2.32
Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol (2011) 2.18
Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol (2013) 2.14
A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol (2009) 2.10
Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. Cell Host Microbe (2008) 2.08
Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. PLoS Pathog (2006) 2.08
Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis (2006) 2.06
Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog (2013) 2.02
Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy. J Gastroenterol (2015) 2.01
Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1. J Infect Dis (2009) 1.93
Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol (2008) 1.91
Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol (2009) 1.89
Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst (2012) 1.88
BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle (2012) 1.88
A long-term latent reservoir for HIV-1: discovery and clinical implications. J Antimicrob Chemother (2004) 1.87
Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology (2008) 1.85
Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J Virol (2004) 1.85
Latency in human immunodeficiency virus type 1 infection: no easy answers. J Virol (2003) 1.83
The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation. J Biol Chem (2008) 1.83
Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T-cell activation. J Virol (2008) 1.82
Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART. PLoS Pathog (2007) 1.81
Chronic CD4+ T-cell activation and depletion in human immunodeficiency virus type 1 infection: type I interferon-mediated disruption of T-cell dynamics. J Virol (2007) 1.77
A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy. Clin Infect Dis (2008) 1.76
Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest (2015) 1.76
Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci U S A (2008) 1.72
Minocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4+ T cells. J Infect Dis (2010) 1.70
A quantitative basis for antiretroviral therapy for HIV-1 infection. Nat Med (2012) 1.68
Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J Virol (2010) 1.66
Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor. J Virol (2008) 1.66
Analysis of human immunodeficiency virus type 1 transcriptional elongation in resting CD4+ T cells in vivo. J Virol (2004) 1.64
The role of protective HCP5 and HLA-C associated polymorphisms in the control of HIV-1 replication in a subset of elite suppressors. AIDS (2008) 1.63
HIV-1 viral load blips are of limited clinical significance. J Antimicrob Chemother (2006) 1.63
Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. J Clin Invest (2013) 1.62
Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. Nat Med (2012) 1.61
UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil. World J Gastroenterol (2012) 1.56
The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients. AIDS (2008) 1.50
Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. PLoS Pathog (2009) 1.49
Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov Today (2012) 1.47
Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J Virol (2007) 1.47
Severe depletion of CD4+ CD25+ regulatory T cells from the intestinal lamina propria but not peripheral blood or lymph nodes during acute simian immunodeficiency virus infection. J Virol (2007) 1.47
A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis (2013) 1.46
No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. J Infect Dis (2010) 1.45
HIV latency and integration site placement in five cell-based models. Retrovirology (2013) 1.42
Can antiretroviral therapy ever be stopped? An update. AIDS Read (2004) 1.42
Evolution of HIV-1 in an HLA-B*57-positive patient during virologic escape. J Infect Dis (2007) 1.41
Developing strategies for HIV-1 eradication. Trends Immunol (2012) 1.38
Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. Clin Infect Dis (2004) 1.34
Influence of host gene transcription level and orientation on HIV-1 latency in a primary-cell model. J Virol (2011) 1.34
Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance. Proc Natl Acad Sci U S A (2011) 1.33
Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Chin J Cancer (2011) 1.32
A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients. J Virol (2005) 1.32
Evidence of CD8+ T-cell-mediated selective pressure on human immunodeficiency virus type 1 nef in HLA-B*57+ elite suppressors. J Virol (2008) 1.31
HIV-1 DNA is detected in bone marrow populations containing CD4+ T cells but is not found in purified CD34+ hematopoietic progenitor cells in most patients on antiretroviral therapy. J Infect Dis (2012) 1.29
Direct priming and cross-priming contribute differentially to the induction of CD8+ CTL following exposure to vaccinia virus via different routes. J Immunol (2002) 1.28
The protein kinase C-responsive inhibitory domain of CARD11 functions in NF-kappaB activation to regulate the association of multiple signaling cofactors that differentially depend on Bcl10 and MALT1 for association. Mol Cell Biol (2008) 1.26
A novel PCR assay for quantification of HIV-1 RNA. J Virol (2013) 1.25
Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs (2010) 1.25
Local sequence targeting in the AID/APOBEC family differentially impacts retroviral restriction and antibody diversification. J Biol Chem (2010) 1.24
Therapeutic vaccination with simian immunodeficiency virus (SIV)-DNA + IL-12 or IL-15 induces distinct CD8 memory subsets in SIV-infected macaques. J Immunol (2008) 1.22
Outwitting evolution: fighting drug-resistant TB, malaria, and HIV. Cell (2012) 1.17
A phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus. Am J Clin Oncol (2008) 1.16
Novel pathway for induction of latent virus from resting CD4(+) T cells in the simian immunodeficiency virus/macaque model of human immunodeficiency virus type 1 latency. J Virol (2006) 1.16
Oncogenic CARD11 mutations induce hyperactive signaling by disrupting autoinhibition by the PKC-responsive inhibitory domain. Biochemistry (2010) 1.16
HIV-1 eradication strategies: design and assessment. Curr Opin HIV AIDS (2013) 1.15
Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART. BMC Infect Dis (2008) 1.15